Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells
Authors:
- 1 May 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 486 (4) , 1069-1076
Abstract
No abstract availableKeywords
Funding Information
- Korea Health Technology R&D
- Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea (HI12C1852)
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning (2015R1C1A2A01053747)
- Korea University Guro Hospital Grant (O1600121)
This publication has 25 references indexed in Scilit:
- STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cellsInternational Journal of Oncology, 2016
- Revisiting STAT3 signalling in cancer: new and unexpected biological functionsNature Reviews Cancer, 2014
- Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like propertiesBritish Journal of Cancer, 2011
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesisNature Reviews Cancer, 2007
- Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome ActivityCancer Research, 2006
- Stem Cells and Cancer: Two Faces of EveCell, 2006
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- STAT proteins: novel molecular targets for cancer drug discoveryOncogene, 2000
- A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolitesActa Psychiatrica Scandinavica, 1992